<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04899232</url>
  </required_header>
  <id_info>
    <org_study_id>20201048</org_study_id>
    <nct_id>NCT04899232</nct_id>
  </id_info>
  <brief_title>Antithrombin III in Infectious Disease Caused by COVID-19</brief_title>
  <official_title>Antithrombin III (AT3) in Infectious Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)/ Coronavirus Disease of 2019 (COVID-19)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Enrique Ginzburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Grifols Biologicals, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to see if participants who have SARS-CoV-2 and low&#xD;
      levels of AT3 in the blood will benefit by being given AT3.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 6, 2021</start_date>
  <completion_date type="Anticipated">December 19, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in ISTH DIC Score</measure>
    <time_frame>Baseline, Day 9</time_frame>
    <description>As measured by the International Society of Thrombosis and Haemostasis Disseminated Intravascular Coagulation scale (ISTH DIC) which has a total score ranging from 0-8 with a score of 5 and higher indicating overt DIC.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in D-Dimer levels</measure>
    <time_frame>Baseline, Day 9</time_frame>
    <description>D-Dimer levels assessed from blood samples will be evaluated in mcg/ml D-Dimer Units (DDU)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fibrinogen Levels</measure>
    <time_frame>Baseline, Day 9</time_frame>
    <description>Fibrinogen levels assessed from blood samples will be evaluated in mg/dL Fibrinogen Equivalent Units (FEU).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Prothrombin time</measure>
    <time_frame>Baseline, Day 9</time_frame>
    <description>Prothrombin time assessed from blood samples will be evaluated in seconds.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Hospital Stay</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Length of Hospital Stay reported in days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality Rate</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Percentage of reported death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary Function</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Pulmonary Function will be reported as the days the participant was on any of the following: mechanical ventilation or Extracorporeal Membrane Oxygenation (ECMO) use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SOFA scores</measure>
    <time_frame>Baseline, Day9</time_frame>
    <description>Sequential Organ Failure Assessment (SOFA) is scored from 0-4 with the higher score indicating more organ failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SOFA Respiratory Sub Score</measure>
    <time_frame>Baseline, Day 9</time_frame>
    <description>SOFA Respiratory Sub Score is scored from 0-4 with the higher score indicating worse organ failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Incidences of venous thromboembolism</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Number of incidences of venous thromboembolisms from admission to hospital discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of incidences of major bleeding</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Number of incidences of major bleeding from admission to hospital discharge.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Antithrombin III Deficiency</condition>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>AT3 less than 100% with SOC plus AT3 supplement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group, with endogenous Antithrombin lll less than 100%, will receive 5 doses of supplemental Antithrombin III on Days 1, 3, 5, 7 and 9, in addition to standard of care (SOC) treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AT3 less than 100% with SOC only</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants in this group, with endogenous Antithrombin III less than 100%, will receive SOC treatment only.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AT3 more than 100% with SOC only</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants in this group, with endogenous Antithrombin III more than 100%, will receive SOC treatment only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antithrombin III</intervention_name>
    <description>Five total doses of daily 1,821 to 9,100 IUs Antithrombin III, depending on participant's weight, will be administered intravenously every other infusion day (Days 1, 3, 5, 7 and 9).</description>
    <arm_group_label>AT3 less than 100% with SOC plus AT3 supplement</arm_group_label>
    <other_name>Thrombate III</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:&#xD;
&#xD;
          1. &gt;18y of age,&#xD;
&#xD;
          2. Subject or proxy who can provide informed consent&#xD;
&#xD;
          3. Positive SARS-COV-2 by Polymerase Chain Reaction (PCR) or as determined by clinical&#xD;
             team&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          1. Adults or Proxy unable to consent&#xD;
&#xD;
          2. Individuals who are not yet adults (infants, children, teenagers)&#xD;
&#xD;
          3. Pregnant women&#xD;
&#xD;
          4. Prisoners&#xD;
&#xD;
          5. Patients expected to die within 24 hours or with a &quot;do not resuscitate&quot; order,&#xD;
&#xD;
          6. Multi-organ failure,&#xD;
&#xD;
          7. History of hypersensitivity or allergy to any component of the study drug,&#xD;
&#xD;
          8. Ongoing massive surgical or unexplained bleeding,&#xD;
&#xD;
          9. History of bleeding or clotting disorder,&#xD;
&#xD;
         10. Severe traumatic brain injury (Glasgow Coma Scale &lt;6),&#xD;
&#xD;
         11. Spinal or multiple-trauma,&#xD;
&#xD;
         12. Cancer (incurable/terminal phase) and/or patients receiving palliative care,&#xD;
&#xD;
         13. Enrollment in another concurrent clinical interventional study if considered&#xD;
             interfering with this study objectives&#xD;
&#xD;
         14. Per study team discretion, any condition(s) that may prevent safe treatment, preclude&#xD;
             adequate evaluation or adding further risk to their underlying illness.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enrique Ginzburg</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Enrique Ginzburg, MD</last_name>
    <phone>305-585-1178</phone>
    <email>eginzbur@med.miami.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Brandon Parker, DO</last_name>
    <phone>305-585-1178</phone>
    <email>bmp55@med.miami.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brandon Parker, DO</last_name>
      <phone>305-585-1178</phone>
      <email>bmp55@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Brandon Parker, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 20, 2021</study_first_submitted>
  <study_first_submitted_qc>May 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2021</study_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Enrique Ginzburg</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infections</mesh_term>
    <mesh_term>Antithrombin III Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antithrombins</mesh_term>
    <mesh_term>Antithrombin III</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

